These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 19911113)
1. Aftercare in patients with Cushing's disease and acromegaly: is there room for improvement? Psaras T; Milian M; Hattermann V; Gallwitz B; Freiman T; Honegger J Acta Neurochir (Wien); 2010 Feb; 152(2):271-8. PubMed ID: 19911113 [TBL] [Abstract][Full Text] [Related]
2. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832 [TBL] [Abstract][Full Text] [Related]
3. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly. Losa M; Garbin E; Pedone E; Mortini P J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842 [TBL] [Abstract][Full Text] [Related]
4. Octreotide as primary therapy for acromegaly. Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [TBL] [Abstract][Full Text] [Related]
5. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390 [TBL] [Abstract][Full Text] [Related]
6. [Outcome of somatostatin analogue treatment in acromegaly]. Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182 [TBL] [Abstract][Full Text] [Related]
7. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Jallad RS; Musolino NR; Salgado LR; Bronstein MD Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910 [TBL] [Abstract][Full Text] [Related]
8. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615 [TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Biermasz NR; van Dulken H; Roelfsema F J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114 [TBL] [Abstract][Full Text] [Related]
10. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408 [TBL] [Abstract][Full Text] [Related]
11. Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients. Evran M; Sert M; Tetiker T BMC Endocr Disord; 2014 Dec; 14():97. PubMed ID: 25511633 [TBL] [Abstract][Full Text] [Related]